Indication
Chronic Kidney Disease
The Chronic Kidney Disease pipeline: 97 tracked drugs, 23 approved for this indication.
23 approved / phase 432 Phase 31 Phase 2/324 Phase 212 Phase 15 preclinical / unstaged
Compare the share prices of listed companies in Chronic Kidney Disease →
Total attributable cost
$646.5B
$17,472/patient
Drug spend
$50.3B
$1,359/patient
8% of total cost is drugs
All stages, non-dialysis (national surveillance estimate, updated 2026-03) · US